DrugTargetInspector: An assistance tool for patient treatment stratification
DrugTargetInspector: An assistance tool for patient treatment stratification
复制标题
DrugTargetInspector：患者治疗分层的辅助工具
DOI：
10.1002/ijc.29897
复制
发表时间：
2016
影响因子：
6.4
通讯作者：
Oliver Kohlbacher
中科院分区：
文献类型：
--
作者：
Schneider;Stöckel;Gerasch;Ludwig;Leidinger;Hanno Huwer;Stefan Tenzer;Oliver Kohlbacher
癌症是一大类疾病，其特征在于一组共同的特征，称为癌症的标志。这些标志之一是获得基因组不稳定性和突变。这与高增殖率和修复机制的失败相结合，导致克隆进化以及肿瘤内的高基因型和表型多样性。因此，恶性肿瘤的治疗和治疗仍然是一个巨大的挑战。此外，在选择性压力下，例如，由化疗引起的耐药亚群可能会出现，然后可能导致复发。为了最大限度地减少发展多药耐药肿瘤细胞群的风险，必须在深入表征肿瘤遗传和表型组成的基础上确定最佳（联合）治疗，这是分层医学和精准医学的一个重要方面。我们提出DrugTargetInspector（DTI），治疗分层的交互式辅助工具。DTI分析基因组、转录组和蛋白质组数据集，并提供有关解除管制的药物靶点、丰富的生物学途径和解除管制的子网络以及突变及其对推定药物靶点和感兴趣基因的潜在影响的信息。为了证明DTI的广泛适用性，我们对几种癌症类型和不同类型的输入组学数据进行了案例研究。DTI的综合方法允许用户根据各种组学数据集来描述正在研究的肿瘤，并根据临床决策指南阐明假定的治疗方案，但也提出了可能被忽视的其他干预点。DTI可在http：//dti.bioinf.uni-sb.de上免费查阅。
Cancer is a large class of diseases that are characterized by a common set of features, known as theHallmarks of cancer. One of these hallmarks is the acquisition of genome instability and mutations. This, combined with high proliferation rates and failure of repair mechanisms, leads to clonal evolution as well as a high genotypic and phenotypic diversity within the tumor. As a consequence, treatment and therapy of malignant tumors is still a grand challenge. Moreover, under selective pressure,e.g., caused by chemotherapy, resistant subpopulations can emerge that then may lead to relapse. In order to minimize the risk of developing multidrug‐resistant tumor cell populations, optimal (combination) therapies have to be determined on the basis of an in‐depth characterization of the tumor's genetic and phenotypic makeup, a process that is an important aspect of stratified medicine and precision medicine. We present DrugTargetInspector (DTI), an interactive assistance tool for treatment stratification. DTI analyzes genomic, transcriptomic, and proteomic datasets and provides information on deregulated drug targets, enriched biological pathways, and deregulated subnetworks, as well as mutations and their potential effects on putative drug targets and genes of interest. To demonstrate DTI's broad scope of applicability, we present case studies on several cancer types and different types of input ‐omics data. DTI's integrative approach allows users to characterize the tumor under investigation based on various ‐omics datasets and to elucidate putative treatment options based on clinical decision guidelines, but also proposing additional points of intervention that might be neglected otherwise. DTI can be freely accessed at http://dti.bioinf.uni‐sb.de.
登录
查看更多内容
DOI：
10.1007/978-1-62703-435-7_20
发表时间：
2013
期刊：
Methods in molecular biology (Clifton, N.J.)
影响因子：
--
作者：
Thorn, Caroline F;Klein, Teri E;Altman, Russ B
通讯作者：
Altman, Russ B
影响因子：
3.7
作者：
Gerasch A;Faber D;Küntzer J;Niermann P;Kohlbacher O;Lenhof HP;Kaufmann M
通讯作者：
Kaufmann M
影响因子：
8
作者：
Zirn, B;Samans, B;Gessler, M
通讯作者：
Gessler, M
影响因子：
48
作者：
Distler, Ute;Kuharev, Joerg;Tenzer, Stefan
通讯作者：
Tenzer, Stefan
NetworkTrail - 用于识别和可视化解除管制的子网络的 Web 服务
影响因子：
5.8
作者：
D. Stöckel;Oliver Müller;Tim Kehl;A. Gerasch;C. Backes;Alexander Rurainski;A. Keller;Michael Kaufmann;H. Lenhof
通讯作者：
H. Lenhof